These experiments demonstrated that CDK6 operates as an enhancer of the transcriptional action of NF-κB, where its blockade led to mitigation of the MPN phenotype through the diminution of NF-κB-dependent inflammation [99]. This evidence concerns the gene NFKB1 and myeloproliferative neoplasm.